Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) CongressBOSTON, October 09, 2026--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress
- SpotifyPodcasters Share Wellness Advice for World Mental Health DayOctober 10 is World Mental Health Day, but for many podcast creators, wellness is a year-round pursuit. Listeners turn to their shows for accessible self-care tools, alongside inspiring stories of resilience, growth, and community. This year, some of the most popular wellness conversations have centered around building better habits and overcoming procrastination. We’ve also seen... The post Podcasters Share Wellness Advice for World Mental Health Day appeared first on Spotify.
- Evidently Expands Clinical Data Intelligence from Patient to PopulationPALO ALTO, Calif., October 09, 2026--Evidently expands Clinical Data Intelligence from patient to population. New tools built on Omni start with a clinician's own patient list.
- Affinia TherapeuticsAffinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026WALTHAM, Mass., October 09, 2026--Affinia Therapeutics ("Affinia"), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that AFTX-201 preclinical and translational data and the Phase 1/2 UPBEAT™ clinical trial investigating AFTX-201 in patients with BAG3-associated dilated cardiomyopathy (DCM), will be featured at the Heart Failure So
- US WorldMedsUS WorldMeds Receives the Sarcoma Foundation of America's 2026 Vision of Hope AwardCompany recognized for advancing treatment options in sarcoma and for embedding the patient advocacy perspective into its development and regulatory work US WorldMeds announced that it received the 2026 Vision of Hope Award from the Sarcoma Foundation of America (SFA). The award was presented on October 6, 2026, at the Stand Up to Sarcoma Gala in New York City, with representatives from across the S
- PhyPalBefore ChatGPT, PhyPal Had the Clinical Evidence but Not the AI. Now It's Back.Clinically studied patient engagement platform relaunches with conversational AI and a California workers' compensation pilot. PhyPal today announced the relaunch of its patient engagement platform, combining modern conversational AI with its original deterministic clinical technology. The updated platform connects patient intake, clinical documentation, outcomes tracking, and treatment authorizatio
- MedincellMedincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)MONTPELLIER, France, October 09, 2026--Medincell (Paris:MEDCL) Medincell will host Investor webcast today to discuss the implications of the approval for the Company and answer questions from analysts.
- Antibody Designed by Spanish Biopharma Oncomatryx Shows That Attacking the Tumor Environment Also Kills Cancer CellsZAMUDIO, Spain, October 09, 2026--Oncomatryx, the Basque biopharmaceutical company pioneering the treatment of solid tumors through their microenvironment, has taken part, together with German research institutions, in a study showing in patient tumor tissue that destroying the cells that protect the tumor also kills cancer cells.
- Milestone Pharmaceuticals Inc. MONTREAL andMilestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical TrialDutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR
- Nuvectis Pharma to Participate in the Maxim Growth Summit 2026Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.
- Nextech Unveils Agentic AI Capabilities for Patient Experience through Partnerships with Assort Health and EliseAINextech partners with Assort Health and EliseAI to bring integrated, 24/7 agentic AI patient access to specialty practices, improving efficiency and care.
- Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalArcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical